18.03
0.06 (0.36%)
| Previous Close | 17.96 |
| Open | 18.00 |
| Volume | 4,736,909 |
| Avg. Volume (3M) | 7,014,778 |
| Market Cap | 12,308,942,848 |
| Price / Sales | 489.39 |
| Price / Book | 2.51 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.00 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 30 Jun 2025 | 59,952,652 |
| Viking Global Investors Lp | 30 Jun 2025 | 34,237,779 |
| Qvt Financial Lp | 30 Jun 2025 | 29,381,635 |
| Patient Square Capital Lp | 30 Jun 2025 | 12,480,000 |
| Anchorage Capital Group, L.L.C. | 30 Jun 2025 | 4,832,642 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Goldman Sachs, 33.15%) | Buy |
| Median | 20.00 (10.96%) | |
| Low | 16.00 (Citigroup, -11.23%) | Buy |
| Average | 19.94 (10.62%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 14.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 18 Sep 2025 | 16.50 (-8.46%) | Hold | 15.09 |
| Goldman Sachs | 18 Sep 2025 | 24.00 (33.15%) | Buy | 15.09 |
| Guggenheim | 18 Sep 2025 | 21.00 (16.50%) | Buy | 15.09 |
| HC Wainwright & Co. | 18 Sep 2025 | 20.00 (10.96%) | Buy | 15.09 |
| JP Morgan | 18 Sep 2025 | 20.00 (10.96%) | Buy | 15.09 |
| Jefferies | 18 Sep 2025 | 20.00 (10.96%) | Buy | 15.09 |
| Leerink Partners | 18 Sep 2025 | 22.00 (22.05%) | Buy | 15.09 |
| Citigroup | 02 Sep 2025 | 16.00 (-11.23%) | Buy | 12.39 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| VENKER ERIC | - | 16.89 | -872,110 | -14,871,149 |
| Aggregate Net Quantity | -872,110 | |||
| Aggregate Net Value ($) | -14,871,149 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.89 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| VENKER ERIC | Officer | 17 Oct 2025 | Automatic sell (-) | 118,418 | 17.26 | 2,043,895 |
| VENKER ERIC | Officer | 17 Oct 2025 | Option execute | 118,418 | - | - |
| VENKER ERIC | Officer | 16 Oct 2025 | Automatic sell (-) | 318,282 | 17.11 | 5,445,805 |
| VENKER ERIC | Officer | 16 Oct 2025 | Option execute | 318,282 | - | - |
| VENKER ERIC | Officer | 15 Oct 2025 | Automatic sell (-) | 414,683 | 16.99 | 7,045,464 |
| VENKER ERIC | Officer | 15 Oct 2025 | Option execute | 414,683 | - | - |
| VENKER ERIC | Officer | 13 Oct 2025 | Automatic sell (-) | 20,727 | 16.21 | 335,985 |
| VENKER ERIC | Officer | 13 Oct 2025 | Option execute | 20,727 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |